CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities
Net loss	$ (40,174)	$ (52,108)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	1,370	525
Amortization (accretion) on marketable securities	0	(182)
Non-cash interest expense	87	87
Non-cash lease expense	634	401
Non-cash (income) expense from collaborative arrangements, net	(2,406)	(1,134)
Stock-based compensation expense	5,551	7,495
Impairment of advance for COVAXIN supply	0	4,074
Loss on disposal of fixed assets related to COVAXIN	0	363
Other	28	379
Changes in assets and liabilities:
Prepaid expenses and other current assets	1,701	132
Accounts payable and accrued expenses	2,048	(10,402)
Lease obligations	(617)	(382)
Net cash used in operating activities	(31,778)	(50,752)
Cash flows from investing activities
Purchases of marketable securities	0	(3,947)
Proceeds from the maturities of marketable securities	0	17,500
Purchases of property and equipment	(3,372)	(7,754)
Net cash (used in) provided by investing activities	(3,372)	5,799
Cash flows from financing activities
Proceeds (payments) from issuance of common stock, net	37,575	20,788
Payment of equity issuance costs	(2,889)	(355)
Proceeds from issuance of debt	0	500
Payment of debt issuance costs	0	(68)
Net cash provided by financing activities	34,686	20,865
Effect of changes in exchange rate on cash and restricted cash	3	2
Net (decrease) in cash and restricted cash	(461)	(24,086)
Cash and restricted cash at beginning of period	39,462	77,563
Cash and restricted cash at end of period	39,001	53,477
Supplemental disclosure of non-cash investing and financing transactions:
Purchases of property and equipment	0	1,969
Series B Convertible Preferred Stock reacquisition	1	0
Right-of-use asset related to operating leases	$ 103	$ 0